Insight

Estela Rodriguez: When more is not necessarily better – SBRT vs conventional RT for Painful Bone Metastases

Estela Rodriguez/X

May 13, 2025, 15:16

Estela Rodriguez: When more is not necessarily better – SBRT vs conventional RT for Painful Bone Metastases

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:

“When more is not necessarily better: SBRT vs conventional RT for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial
(N=126) SBRT failed to demonstrate statistically significant improvement in CR rates after 1 month.”

Title: Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial

Authors: Carole Mercier, Charlotte Billiet, Piet Ost, Katrien Vandecasteele, Geert De Kerf, Michaël Claessens, Steven Van Laere, Peter Vermeulen, Luc Dirix, Yolande Lievens, Dirk Verellen, Piet Dirix

Read the Full Article in Journal of Clinical Oncology.

Estela Rodriguez

cancer Carole Mercier Charlotte Billiet Dirk Verellen Estela Rodriguez Geert De Kerf Katrien Vandecasteele Luc Dirix Michaël Claessens OncoDaily Oncology Peter Vermeulen Piet Dirix Piet Ost Steven Van Laere Yolande Lievens

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...